Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...

Atherosclerosis IV: Nursing Management

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sleep disturbances in patients with vasculitis.

Sleep medicine·2026

Same author

Patients' perspectives of eosinophilic granulomatosis with polyangiitis within the context of a clinical trial.

EULAR rheumatology open·2026

Same author

IgG4-related disease presenting as an omental mass.

BMJ case reports·2026

Same author

Correction: Comprehensive immune profiling identifies alterations in adaptive and innate immune responses in granulomatosis with polyangiitis patients in remission.

Frontiers in immunology·2026

Same author

Comprehensive immune profiling identifies alterations in adaptive and innate immune responses in granulomatosis with polyangiitis patients in remission.

Frontiers in immunology·2026

Same author

Effect of vitamin D treatment in ANCA-associated vasculitis: results from an exploratory perspective, pragmatic, non-randomised study.

Clinical and experimental rheumatology·2026

Same journal

Anti IL-6 Treatment for Calcium Pyrophosphate Disease Report of 4 Cases and a Short Literature Review.

European journal of rheumatology·2026

Same journal

Unmasking Eosinophilic Granulomatosis with Polyangiitis: A Case of Rapid-Onset Myositis Following COVID-19 Booster in an Eosinophilic Asthma Patient.

European journal of rheumatology·2026

Same journal

Eosinophilic Granulomatous Polyangiitis Emerging After Omalizumab Administration: An Asthma Patient Without Systemic Corticosteroids Develops Mononeuritis Multiplex After 22 Days.

European journal of rheumatology·2026

Same journal

Rowell Syndrome with Lupus Podocytopathy: A Diagnostic Challenge.

European journal of rheumatology·2026

Same journal

Disease Course of Axial Spondyloarthritis in Pregnancy.

European journal of rheumatology·2026

Same journal

Regression of a Refractory Pulmonary Lesion in Granulomatosis with Polyangiitis Following the Addition of Avacopan.

European journal of rheumatology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 13, 2026

The Rodent Model of Nonarteritic Anterior Ischemic Optic Neuropathy rNAION

The Rodent Model of Nonarteritic Anterior Ischemic Optic Neuropathy rNAION

Published on: November 20, 2016

Updates in ANCA-associated vasculitis.

Christian Pagnoux¹

¹Department of Medicine, Division of Rheumatology, Vasculitis Clinic, Mount Sinai Hospital, University Health Network, University of Toronto, Ontario, Canada.

European Journal of Rheumatology

|October 14, 2016

Summary

This summary is machine-generated.

Antineutrophil cytoplasm antibody (ANCA)-associated vasculitides research is active, focusing on pathogenic roles of MPO-ANCA and PR3-ANCA. Treatment strategies are evolving, with ongoing efforts to personalize maintenance therapy for ANCA vasculitis.

Keywords:

Antineutrophil cytoplasmic antibody-associated vasculitis Churg-Strauss syndrome (eosinophilic granulomatosis with polyangiitis)cyclophosphamide granulomatosis with polyangiitis (Wegener’s granulomatosis)microscopic polyangiitis rituximab

More Related Videos

A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay

A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay

Published on: December 7, 2021

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

Related Experiment Videos

Last Updated: Mar 13, 2026

The Rodent Model of Nonarteritic Anterior Ischemic Optic Neuropathy rNAION

The Rodent Model of Nonarteritic Anterior Ischemic Optic Neuropathy rNAION

Published on: November 20, 2016

A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay

A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay

Published on: December 7, 2021

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

Area of Science:

Immunology
Nephrology
Rheumatology

Background:

ANCA-associated vasculitides (AAV) encompass granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and renal-limited AAV.
While the cause remains unknown, ANCA-associated vasculitides research has significantly advanced.
The pathogenic role of antimyeloperoxidase ANCA (MPO-ANCA) is supported by animal models, unlike antiproteinase 3 ANCA (PR3-ANCA).

Approach:

Investigating the pathogenic roles of MPO-ANCA and PR3-ANCA in ANCA-associated vasculitides.
Exploring the involvement of B cells, T-cell subtypes, and cytokine-chemokine networks in pathogenesis.
Examining the role of the alternative complement pathway and its blockade in preventing renal disease.

Key Points:

Specific MPO-ANCA subsets targeting certain epitopes correlate with disease activity, requiring advanced detection methods.
Genetic associations appear stronger with ANCA type than clinical diagnosis.
B cells are implicated in ANCA production and immune dysregulation.

Conclusions:

Induction therapy for severe ANCA-associated vasculitides typically involves glucocorticoids plus cyclophosphamide or rituximab.
Treatment choices depend on patient factors like comorbidities, pregnancy plans, and prior treatments.
Optimal maintenance strategies, especially after rituximab induction, and duration of therapy require further research.